Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Combined Magnetic Stimulation and Ultrasound for Detrusor Overactivity in SCI

9 november 2026 uppdaterad av: Xue Jiang, Shengjing Hospital

A Randomized, Double-Blind, Sham-Controlled Trial of Sacral Nerve Root High-Frequency Magnetic Stimulation Combined With Ultrasound Therapy for Detrusor Overactivity in Patients With Spinal Cord Injury

This clinical trial aims to investigate whether the combination of high-frequency sacral nerve root magnetic stimulation and bladder-directed ultrasound therapy can effectively improve detrusor overactivity (involuntary bladder contractions) and related voiding dysfunctions in patients with spinal cord injury. The main questions it seeks to answer are:

What is the effect of high-frequency sacral nerve root magnetic stimulation on detrusor overactivity and bladder function in patients with spinal cord injury?

What is the effect of bladder-directed ultrasound therapy on detrusor overactivity and bladder wall compliance in patients with spinal cord injury?

Is the combination of these two treatment modalities superior to magnetic stimulation alone?

Studieöversikt

Detaljerad beskrivning

Researchers will combine high-frequency sacral nerve root magnetic stimulation with bladder ultrasound therapy and compare this combination against magnetic stimulation alone (with sham ultrasound) to determine whether the combined approach provides added benefit.

Participants will:

Receive either sacral nerve root magnetic stimulation, bladder ultrasound therapy, or the combination of both, once daily for 3 consecutive weeks (7 sessions per week).

Attend the hospital for urodynamic testing (to assess safe bladder capacity, storage pressure, and compliance) and urinary tract ultrasound (to evaluate bladder wall thickness and upper urinary tract structure) before the treatment and after the 3-week intervention.

Maintain a voiding diary for at least 3 consecutive days (recording single voided volumes, urgency scores, and incontinence episodes), and complete validated questionnaires on lower urinary tract symptoms and quality of life.

Studietyp

Interventionell

Inskrivning (Beräknad)

44

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Shenyang, Kina
        • Rekrytering
        • Rehabilitation Center of Shengjing Hospital, China Medical University, shenyang, Liaoning 110000
        • Kontakt:
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Diagnosis of spinal cord injury (SCI) above the sacral level according to the International Standards for Neurological Classification of Spinal Cord Injury (revised 2011), confirmed by CT or MRI;
  2. Detrusor overactivity confirmed by urodynamic study;
  3. No severe urinary system diseases such as tumors, stones, infection, or organic urinary tract obstruction;
  4. No severe hepatic/renal insufficiency, pulmonary, or cardiovascular diseases;
  5. Aged 18-80 years;
  6. Able to understand and comply with the required examinations, rehabilitation assessments, and treatment, and provide written informed consent.

Exclusion Criteria:

  1. Unstable vital signs or critically ill condition;
  2. Severe autonomic dysreflexia;
  3. Presence of metallic implants within 10 cm of the magnetic stimulation treatment area;
  4. Any other diseases or conditions that may interfere with the study outcomes.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Experimental Group: Sacral Nerve Root Magnetic Stimulation + Active Ultrasound Therapy

Magnetic stimulation: round coil over S3 foramina, verified by toe twitch. 20 Hz intermittent, 1000 pulses/session, intensity 55%-100% max. Active ultrasound: after saline infusion with pressure monitoring (stop at 40 cmH₂O or discomfort), 1.0 MHz, 1.5-2.0 W/cm², 1000 μs PRP, 1:4 duty cycle, 200 μs pulse duration. Probe moved over suprapubic area, 20 min/session. Both given once daily, 7 days/week for 3 weeks. Stop immediately if pressure >40 cmH₂O or any discomfort.

Participants receive the intervention assigned to their group 7 days per week for 3 weeks.

Sham Comparator: Control Group: Sacral Nerve Root Magnetic Stimulation + Sham Ultrasound Therapy

Magnetic stimulation: identical to Arm 1. Sham ultrasound: same probe, same interface settings (frequency, intensity display, pulse parameters) but zero output power. Bladder infusion and pressure monitoring same as Arm 1. Probe moved over suprapubic area for 20 min/session. Treatment frequency and duration identical to Arm 1 (once daily, 7 days/week, 3 weeks). Stop if pressure >40 cmH₂O or discomfort.

Participants receive the intervention assigned to their group 7 days per week for 3 weeks.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Bladder capacity at first detrusor overactivity
Tidsram: Baseline and immediately after 3-week intervention

Measured by urodynamic study. The volume at which involuntary detrusor contraction first occurs during bladder filling. Target safe capacity ≥300 ml.

Baseline and immediately after 3-week intervention

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Urodynamic parameters-Bladder compliance
Tidsram: Baseline and immediately after 3-week intervention

reflecting bladder wall elasticity, calculated as the change in bladder volume divided by the change in detrusor pressure, ΔV/ΔP

Baseline and immediately after 3-week intervention
Chinese version of the Neurogenic Bladder (NB) Brief Health Survey
Tidsram: Baseline and immediately after 3-week intervention

assessing the impact of neurogenic bladder on overall health status and daily living

Baseline and immediately after 3-week intervention
Voiding diary parameters
Tidsram: Baseline and after 3-week intervention

Includes single-void volume, urgency score, and incontinence episodes, recorded over at least 72 consecutive hours.

Baseline and after 3-week intervention
Urodynamic parameters-First sensation of bladder filling
Tidsram: Baseline and immediately after 3-week intervention

the infused volume at which the subject first perceives the initial urge to void

Baseline and immediately after 3-week intervention
Infection-related indicators-Urine white blood cell (WBC) count
Tidsram: Baseline and immediately after 3-week intervention

an objective laboratory quantitative indicator of urinary tract infection

Baseline and immediately after 3-week intervention
Antibiotic utilization rate
Tidsram: Baseline and immediately after 3-week intervention

calculated as defined daily doses per treatment cycle, reflecting the frequency of antibiotic intervention due to infection during the treatment period

Baseline and immediately after 3-week intervention
Urodynamic parameters-Detrusor leak point pressure
Tidsram: Baseline and immediately after 3-week intervention

the detrusor pressure at the moment of urinary leakage during storage, reflecting urethral closure reserve

Baseline and immediately after 3-week intervention
Urodynamic parameters-Maximum detrusor contraction pressure
Tidsram: Baseline and immediately after 3-week intervention

the peak detrusor pressure achieved during the voiding phase

Baseline and immediately after 3-week intervention
Urodynamic parameters-Duration of detrusor contraction
Tidsram: Baseline and immediately after 3-week intervention

the total time of sustained effective detrusor contraction during voiding

Baseline and immediately after 3-week intervention
Overactive Bladder Symptom Score (OABSS)
Tidsram: Baseline and immediately after 3-week intervention

quantifying the severity of lower urinary tract symptoms including frequency, urgency, and urgency incontinence

Baseline and immediately after 3-week intervention
Voiding difficulty score
Tidsram: Baseline and immediately after 3-week intervention

assessing subjective symptoms such as straining, weak stream, and hesitancy

Baseline and immediately after 3-week intervention
Quality of Life score (QoL)
Tidsram: Baseline and immediately after 3-week intervention

evaluating the interference of lower urinary tract dysfunction with daily activities, social functioning, and emotional well-being

Baseline and immediately after 3-week intervention
Bladder wall thickness
Tidsram: Baseline and immediately after 3-week intervention

measured by ultrasound, reflecting detrusor hypertrophy or fibrotic changes

Baseline and immediately after 3-week intervention
Bladder tissue architecture / morphology
Tidsram: Baseline and immediately after 3-week intervention

including wall layering clarity, mucosal surface regularity, and internal echogenicity uniformity

Baseline and immediately after 3-week intervention
Upper urinary tract dilation, pelvicalyceal system separation, and hydronephrosis
Tidsram: Baseline and immediately after 3-week intervention

comprehensively assessing the degree of ureteral and pelvicalyceal dilatation as structural indicators of upper urinary tract damage risk

Baseline and immediately after 3-week intervention

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Xue Jiang, Rehabilitation Center of Shengjing Hospital, China Medical University

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 juli 2026

Primärt slutförande (Beräknad)

30 april 2027

Avslutad studie (Beräknad)

30 april 2027

Studieregistreringsdatum

Först inskickad

6 juli 2026

Först inskickad som uppfyllde QC-kriterierna

9 juli 2026

Första postat (Faktisk)

15 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

10 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera